Skip to main content

Cyteir Therapeutics, Inc. (CYT)

NASDAQ: CYT · IEX Real-Time Price · USD
15.44 -0.19 (-1.22%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap546.11M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out2.34M
EPS (ttm)-14.90
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume19,010
Open15.54
Previous Close15.63
Day's Range15.28 - 16.60
52-Week Range14.00 - 23.10
Betan/a
Analystsn/a
Price Target31.50 (+104.0%)
Est. Earnings DateNov 8, 2021

About CYT

Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality represents a clinically validated approach to drug development and arises when there is a deficiency in either of two conditions that are tolerable alone in cells but lethal together. Our lead program, CYT-0851, is in a phase 1...

IndustryBiotechnology
IPO DateJun 18, 2021
CEOMarkus Renschler, M.D.
Employees22
Stock ExchangeNASDAQ
Ticker SymbolCYT
Full Company Profile

Financial Performance

Financial Statements

News

Cyteir Therapeutics Selected to Join Russell 2000® Index

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was...

6 days ago - Business Wire

Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...

3 weeks ago - Business Wire

Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

1 month ago - Business Wire

Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...

1 month ago - Business Wire

Cyteir Therapeutics Announces Closing of Initial Public Offering

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

3 months ago - Business Wire

Cyteir Therapeutics Announces Pricing of Initial Public Offering

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

3 months ago - Business Wire

Cyteir Therapeutics IPO Registration Document (S-1)

Cyteir Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC